GlassScriptPhysician profile
Ali I Moustapha
NPI 1740244730
$5,679.74
in general payments reported to CMS, 2019-2025
36 companies · $625 in 2025
The $625 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $1,060 · 2021: $760 · 2022: $743 · 2023: $1,042 · 2024: $616 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,282.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $775.08 | 2020-2025 | Lifevest |
| Boston Scientific Corporation | $734.25 | 2019-2025 | Avvigo Guidance System, Watchman Flx, Accolade Sr |
| Novartis Pharmaceuticals Corporation | $643.83 | 2020-2025 | |
| Medtronic Vascular, INC. | $505.68 | 2019-2020 | |
| Pfizer INC. | $369.74 | 2019-2025 | |
| Amgen INC. | $346.82 | 2019-2025 | Repatha, Repatha |
| Welch Allyn | $300.71 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $269.21 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $229.55 | 2020-2025 | Jot Dx, Assurity, Thoratec Heartmate 3 Lvas Implant Kit |
| Medicure Pharma INC. | $224.42 | 2020-2021 | |
| Bardy Diagnostics, INC. | $150.95 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $117.46 | 2019-2024 | Farxiga |
| Medtronic, INC. | $93.99 | 2022-2025 | Symplicity G3, Corevalve Evolut R |
| Novo Nordisk INC | $84.60 | 2024-2025 | Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $69.76 | 2021-2023 | Verquvo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.36 | 2020-2025 | Jardiance |
| Cvrx, INC. | $61.14 | 2023-2024 | Barostim Neo System |
| Biotronik INC. | $59.40 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $56.92 | 2019 | |
| Daiichi Sankyo INC. | $54.34 | 2022-2023 | Injectafer |
| Sanofi-Aventis U.S. LLC | $47.91 | 2019-2023 | |
| Edwards Lifesciences Corporation | $47.67 | 2020-2022 | |
| Cardiovascular Systems INC. | $46.80 | 2019-2020 | |
| Amarin Pharma, INC. | $43.11 | 2020-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $36.63 | 2021-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $36.38 | 2021 | |
| Angiodynamics, INC. | $31.82 | 2021-2022 | |
| Agepha Pharma Fz LLC | $28.42 | 2024 | Lodoco |
| Janssen Pharmaceuticals, INC | $24.55 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $22.56 | 2023 | Inpefa |
| Esperion Therapeutics, INC. | $20.39 | 2021 | |
| Inspire Medical Systems, INC. | $19.14 | 2025 | Inspire |
| Tactile Systems Technology INC | $16.85 | 2021 | |
| G Medical Diagnostic Services, INC. | $14.94 | 2022 | |
| Heartflow, INC. | $14.25 | 2023 | Ffrct |
| Althera Pharmaceuticals LLC | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Moustapha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.